Search results for "Multiple-Myeloma"

showing 4 items of 4 documents

Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion.

2013

Tumor-growth is often associated with the expansion of myeloid derived suppressor cells that lead to local or systemic arginine depletion via the enzyme arginase. It is generally assumed that this arginine deficiency induces a global shut-down of T cell activation with ensuing tumor immune escape. While the impact of arginine depletion on polyclonal T cell proliferation and cytokine secretion is well documented, its influence on chemotaxis, cytotoxicity and antigen specific activation of human T cells has not been demonstrated so far. We show here that chemotaxis and early calcium signaling of human T cells are unimpaired in the absence of arginine. We then analyzed CD8(+) T cell activation…

Cytotoxicity Immunologiclcsh:MedicineCD8-Positive T-LymphocytesARGINASELymphocyte ActivationGranzymesInterleukin 21Cytotoxic T cellIL-2 receptorlcsh:ScienceCells CulturedMultidisciplinarybiologyT CellsChemotaxisVaccinationCOFILINCD28Natural killer T cellCANCERmedicine.anatomical_structureMedicineScience & Technology - Other TopicsImmunotherapyResearch ArticleTumor ImmunologyEXPRESSIONINFILTRATING LYMPHOCYTESCARCINOMAGeneral Science & TechnologyT cellImmune CellsImmunologyArginineImmune SuppressionDENDRITIC CELLSImmunomodulationInterferon-gammaMART-1 AntigenMULTIPLE-MYELOMAMD MultidisciplinarymedicineImmune ToleranceHumansCalcium SignalingAntigen-presenting cellBiologyCell ProliferationCD40Science & TechnologyMULTIDISCIPLINARY SCIENCESPerforinlcsh:RImmunityImmunoregulationIN-VITROImmunologic SubspecialtiesMolecular biologybiology.proteinMYELOID SUPPRESSOR-CELLSClinical ImmunologyTumor Escapelcsh:QT-Lymphocytes CytotoxicPLoS ONE
researchProduct

Phase ia/ii, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematolo…

2013

Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces apoptosis in leukemic cell lines. A phase Ia/II study was designed to determine the maximum-tolerated dose (MTD) of daily panobinostat, administered on two schedules: three times a week every week or every other week on a 28-day treatment cycle in patients with advanced hematologic malignancies. The criteria for hematologic dose-limiting toxicities differed between patients with indications associated with severe cytopenias at baseline (leukemia and myeloid disorders) and those less commonly associated with baseline cytopenias (lymphoma and …

MaleOncologyCancer ResearchIndolesMyeloidhodgkin lymphomahydroxamic acidAdministration Oralresponse criteriaPharmacologyHydroxamic Acidst-cell lymphomaHistoneschemistry.chemical_compoundhemic and lymphatic diseasesAged 80 and overHematologyMiddle AgedLeukemiaTreatment Outcomemedicine.anatomical_structuremyelomaOncologyvorinostatHematologic NeoplasmsFemaleAdultmedicine.medical_specialtypanobinostatrefractory multiple-myelomaMaximum Tolerated DoseAntineoplastic AgentsmyelofibrosisNeutropeniahistone deacetylase inhibitorsmyelodysplastic disordersDrug Administration ScheduleYoung AdultInternal medicinePanobinostatmedicineHumansIn patientAdverse effectMyelofibrosisAgedNeoplasm Staginginternational-working-groupacetylationbusiness.industrymedicine.diseaseLymphomachemistryhistone deacetylasehypoxia-inducible factor-1-alphalbh589business
researchProduct

The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.

2016

IF 7.932; International audience; Graft versus host disease (GvHD), which is the primary complication of allogeneic bone marrow transplantation, can alter the intestinal barrier targeted by activated donor T-cells. Chemical inhibition of the stress protein HSP90 was demonstrated in vitro to inhibit T-cell activation and to modulate endoplasmic reticulum (ER) stress to which intestinal cells are highly susceptible. Since the HSP90 inhibitor 17-allylamino-demethoxygeldanamycin (17AAG) is developed in clinics, we explored here its ability to control intestinal acute GvHD in vivo in two mouse GvHD models (C57BL/6 -> BALB/c and FVB/N -> Lgr5-eGFP), ex vivo in intestine organoids and in vitro in …

0301 basic medicineX-Box Binding Protein 1Cancer ResearchLactams MacrocyclicRNA SplicingT-CellsGraft vs Host Disease[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiology[ SDV.CAN ] Life Sciences [q-bio]/CancerHsp90 inhibitor03 medical and health sciencesMiceSensitivityInflammatory-Bowel-diseaseGeneticsmedicineBenzoquinonesAnimals[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyNeural progenitor cellsHSP90 Heat-Shock ProteinsIntestinal MucosaStem Cell Niche[ SDV.GEN.GH ] Life Sciences [q-bio]/Genetics/Human genetics[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyMolecular BiologyLeukemia[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyBone-Marrow-TransplantationMoleculesmedicine.diseaseStem cell niche3. Good healthIre1-AlphaIntestinesMice Inbred C57BL030104 developmental biologyGraft-versus-host diseaseEr Stress[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsCytoprotectionImmunologyMultiple-MyelomaFemaleOncogene
researchProduct

Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhi…

2014

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease of controversial origin recently recognized as a neoplasm deriving from plasmacytoid dendritic cells (pDCs). Nevertheless, it remains an orphan tumor with obscure biology and dismal prognosis. To better understand the pathobiology of BPDCN and discover new targets for effective therapies, the gene expression profile (GEP) of 25 BPDCN samples was analyzed and compared with that of pDCs, their postulated normal counterpart. Validation was performed by immunohistochemistry (IHC), whereas functional experiments were carried out ex vivo. For the first time at the molecular level, we definitely recognized the cellular derivati…

EXPRESSIONMyeloidCancer ResearchPathologymedicine.medical_specialtyMyeloidCell Cycle; Dendritic Cells; Humans; Leukemia Myeloid Acute; NF-kappa B; Signal Transduction; Gene Expression Profiling; Hematology; Cancer Research; Anesthesiology and Pain MedicineAcuteBiologyCell Cycle; Dendritic Cells; Humans; Leukemia Myeloid Acute; NF-kappa B; Signal Transduction; Gene Expression ProfilingDendritic CellArticleMALIGNANCIESMULTIPLE-MYELOMABlastic plasmacytoid dendritic cell neoplasmBlastic plasmacytoid dendritic cell neoplasm; anti-NF-kB-treatment; GEPGene expressionmedicineHumansNeoplasmanti-NF-kB-treatmentGene Expression ProfilingCell CycleNF-kappa BleukemiaIN-VITRODendritic CellsHematologyBlastic plasmacytoid dendritic cell neoplasmmedicine.diseaseCANCERGEPFACTOR-KAPPA-BLeukemia Myeloid AcuteSettore MED/15 - MALATTIE DEL SANGUEDIFFERENTIATIONAnesthesiology and Pain Medicinemedicine.anatomical_structureLYMPHOID PATHWAYSOncologyCell cultureHEMATODERMIC NEOPLASMImmunohistochemistryCellular modelEx vivoHumanSignal Transduction
researchProduct